Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.

Inclusion Criteria:

• Fully understand the study and voluntarily sign the informed consent form.
• Male or female 18-70 years of age.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
• Histologically confirmed recurrent or metastatic neuroendocrine carcinoma
• Life expectancy ≥ 3 months.

Exclusion Criteria:

• Medical history, computed tomography or magnetic resonance imaging results indicate that existence of the central nervous system metastases;
• Any other malignancy within 5 years.
• participants were deemed unsuitable for participating in the study by the investigator for any reasons.